State of Tennessee Department of Treasury Has $2.80 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

State of Tennessee Department of Treasury trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 58,621 shares of the biopharmaceutical company’s stock after selling 1,654 shares during the quarter. State of Tennessee Department of Treasury’s holdings in Halozyme Therapeutics were worth $2,803,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after buying an additional 386,618 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Halozyme Therapeutics by 2.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company’s stock valued at $92,446,000 after purchasing an additional 47,795 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Halozyme Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company’s stock worth $85,254,000 after purchasing an additional 9,780 shares during the last quarter. Norges Bank acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter worth about $60,054,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Halozyme Therapeutics by 141.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock valued at $47,470,000 after purchasing an additional 581,475 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,200 shares of company stock worth $1,286,568. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 2.1 %

HALO opened at $60.49 on Monday. The firm has a 50 day simple moving average of $60.50 and a 200 day simple moving average of $55.14. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.97 and a fifty-two week high of $66.00. The company has a market cap of $7.47 billion, a price-to-earnings ratio of 17.64, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. raised their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a report on Monday, April 21st. Piper Sandler lifted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday. Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Benchmark reiterated a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $62.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.